Novo Nordisk + OpenAI Deal

Novo Nordisk is rolling out OpenAI tools across its business, aiming to speed drug discovery and use artificial intelligence in day-to-day operations by the end of 2026. (reuters.com) The Danish drugmaker said the partnership will cover research and development, manufacturing, commercial work and employee training, with pilot programs starting in those areas first. Novo Nordisk said OpenAI’s systems will be used to analyze large datasets, spot patterns and test ideas faster. (european-biotechnology.com) Novo Nordisk said the rollout will be global and will include data-protection rules, governance controls and human oversight. OpenAI has been pitching life-sciences customers on tools for research, manufacturing, regulatory work and commercial operations, with privacy terms that say customer data is not used for training. (european-biotechnology.com, openai.com) Drug discovery is the front end of the business: researchers sift through huge amounts of biology and chemistry data to find molecules worth testing. Novo Nordisk said artificial intelligence can help its teams analyze data at a scale that was previously out of reach and shorten the path from research to new treatments. (european-biotechnology.com) The deal lands as Novo Nordisk is trying to move faster in obesity and diabetes after a turbulent 2025. In its annual report, the company said it was “acting urgently” to strengthen its portfolio and defend its position in the increasingly competitive market for glucagon-like peptide-1, or GLP-1, medicines. (novonordisk.com) Novo Nordisk’s obesity-care sales reached 82.3 billion Danish kroner in 2025, up 31% at constant exchange rates, and the company said it treated 45.6 million people living with obesity and diabetes. The same report said Novo launched a company-wide transformation that included cutting about 9,000 jobs and redirecting savings toward growth in obesity and diabetes. (novonordisk.com, novonordisk.com) OpenAI is pushing the same company-wide message to other large employers. On April 8, OpenAI said enterprise now makes up more than 40% of its revenue and described its strategy as embedding artificial intelligence across entire businesses rather than limiting it to isolated software tools. (openai.com) Novo Nordisk’s next scheduled financial update is its first-quarter 2026 report on May 6. By then, investors will be watching whether this partnership stays a pilot program or becomes part of the operating system Novo Nordisk uses to chase its next obesity and diabetes medicines. (novonordisk.com)